Sionna Therapeutics, Inc.
NASDAQ:SIONBiotechnology
+$0.68 today
- Market cap
- $134.35M
- Beta
- 1.29
- P/E (TTM)
- -19.7
- EPS (TTM)
- -$1.90
Volume 0.52M
Average 0.39M
SION Total Current Assets
All assets expected to be converted to cash or used up within one year.
Sionna Therapeutics, Inc.NASDAQ: SION
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets falls 19.3% from a year ago
Total current assets stood at $220.96M at the end of Q1 FY2026, down 19.3% from a year earlier and down 8.5% from the prior quarter. Over 3 fiscal years it compounded at +42.3% a year.
Context
- Total current assets amounted to 72.4% of total assets at the end of Q1 FY2026, down 1.6 pp from a year earlier.
- Total current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps falling in the next quarterly balance sheet after a -19.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 241.42M USD
- Year-over-year change
- +59.9%
- 3-year CAGR
- +42.3%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 241.42M | +59.9% |
| FY2024 | 2024-12-31 | 150.99M | +285.1% |
| FY2023 | 2023-12-31 | 39.21M | -53.2% |
| FY2022 | 2022-12-31 | 83.83M | — |
Total Current Assets vs competitors
How SION compares with its peers on the latest reported figures
- SION's Mar 2026 total current assets of $220.96M is the lowest of the 11 companies compared; the peer median is $502.64M.
- Its year-over-year change of -19.3% is the 10th highest of 11, against a peer median of +24.1%.
- Total current assets amounts to 72.4% of total assets for SION, versus a peer median of 85.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $1B | -2.1% | +43.2% | 97.5% | |
| Sep 2026 | $876.16M | +26.0% | -10.8% | 58.4% | |
| Sep 2026 | $663.74M | +9.8% | +18.9% | 92.0% | |
| Sep 2026 | $532.4M | +82.5% | -24.6% | 45.3% | |
| Jun 2026 | $527.49M | -7.7% | +79.7% | 99.0% | |
| Sep 2026 | $477.8M | +70.7% | +207.8% | 94.5% | |
| Mar 2026 | $381.87M | +22.1% | +35.5% | 75.7% | |
| Mar 2026 | $379.78M | +26.7% | +48.8% | 90.5% | |
| Jun 2026 | $296.56M | -37.5% | -14.4% | 80.0% | |
| Mar 2026 | $251.68M | +53.9% | +8.8% | 64.2% | |
| Mar 2026 | $220.96M | -19.3% | +42.3% | 72.4% | |
| Peer median (excluding SION) | $502.64M | +24.1% | +27.2% | 85.2% | |
Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Sionna Therapeutics, Inc.
NASDAQ:SION
Intrinsic Alpha fair value
Locked
Current Price
$2.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.